Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Eli Lilly

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

The once-daily pill offers a needle-free alternative to injectables, with a U.S. decision anticipated in early 2026.

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study